万维提示：
1、投稿方式：在线投稿。
2、官网网址：https://academic.oup.com/neuro-oncology
3、官网网址：http://www.editorialmanager.com/n-o/
4、官网邮箱：neuonc.editorialoffice@oup.com（编辑部）
5、期刊刊期：月刊，一个月出版一期。
2021年4月28日星期三
投稿须知
【官网信息】
Manuscript preparation instructions
Types Of Articles Published
The following types of unsolicited articles are published in Neuro-Oncology :
Basic and Translational Investigations or Clinical Investigations that report original experimental, translational, clinical, epidemiological, quality-of-life, or other studies relating to neuro-oncology and that are well documented, novel, and significant; included in this group are Phase 1–4 clinical trials reports.
Metadata Analyses/Reviews based on detailed systematic analyses of clinical trials and studies that clearly delineate novel findings or solidify previously less well-substantiated results.
Reviews and Editorials that cover subjects of timely interest and importance to cancer researchers. (These are usually written by invitation of the Editor in Chief. Authors wishing to write a review or an editorial should send a letter to the Editor in Chief outlining the proposed article. All reviews that the editors consider suitable, whether invited or not, will be subjected to full peer review.)
Letters to the Editor offering considered opinions on manuscripts published in the journal within the last 6 months (correspondence concerning articles that have not been published in Neuro-Oncology will not be considered). Letters containing brief results or technical notes of interest to the neuro-oncology community may also be considered for publication. Case studies may be submitted as a letter; however, authors are discouraged from submitting them except when the case is of extraordinary importance.
Fast-Track Articles constitute a small minority of papers of particular importance that will be considered on a case-by-case basis. Authors should contact the Editor-In-Chief in advance to see whether their paper is eligible. These papers will be peer reviewed within 5 days and if accepted, published online in 4-6 weeks.
The following types of articles typically are solicited by the Editor-in-Chief:
Symposia on subjects selected by the Editor-in-Chief
Invited Meeting Reports selected and invited by the Editor-in-Chief
Book Reviews by invitation of the Editor-in-Chief (if you are interested in reviewing books for Neuro-Oncology, please contact the Editorial Office)
Announcements of scientific meetings and courses of interest to Neuro-Oncology readers should be submitted to Jennie Taylor.
Cover Letter And Declarations
A cover letter addressed to the editor, uploaded as a separate Word (.doc or .docx) file, should include the following statements:
Declare whether 1) your manuscript, or any part of it, has been previously published or submitted concurrently to any other journal, and 2) whether all co-authors have read and approved of its submission to this journal.
In addition, declare that you agree to pay for full color reproduction (approximately £350/$600/€525 per figure) if you are submitting color figures with your manuscript. Please note that it is not possible to have color online and black and white in print in order to save costs. (Online supplementary figures are free of charge.)
Manuscript Format
Your manuscript will be returned to you if it exceeds the word limit (see below) or if some items are missing. Only manuscripts fulfilling the formatting specifications will be forwarded to the editor for consideration.
The preferred software for text is Microsoft Word, although manuscripts generated in other word processing programs are acceptable if saved in Rich Text Format. Papers prepared using desktop publishing software are not acceptable. The preferred software for illustrations is described in the Figures & Illustrations section.
The manuscript text (title page, abstract, article text, acknowledgments, reference list, and figure captions), figures, and tables (in .doc, .docx, or .rtf format) should preferably be submitted as separate files. This applies to the original version of the manuscript and any revised versions.
“Author-friendly” submission: For the first submission only (not revised papers), the entire manuscript, including, text, tables, and figures may be uploaded in a single Word file. The supplement (if any) should, however, be uploaded separately. Note, in any case, that PDF files are not acceptable. Display items (tables and figures) should be placed at the end of the text, after the reference list and figure legends.
Basic format for Basic and Translational Investigations and Clinical Investigations articles
The basic format for basic and translational investigations and clinical investigations, including reports of clinical trials, is described here. (Articles with unique formatting requirements such as editorials or review articles are covered below).
Basic and translational investigations and clinical investigations should adhere to the following guidelines:
250-word abstract (maximum)
150-word (maximum) summary entitled "Importance of the Study"
6500-word limit for all words in entire manuscript file*, including title page(s), abstract, importance, manuscript text, acknowledgements, references, and figure legends (but not tables)
6 display items (figures and/or tables)
50 references (maximum)
*Please do not include supplementary legends in the main manuscript file.
Title page
Title, not to exceed 160 characters and spaces
Authors’ full names: given name(s) followed by surname
Affiliation of each author at the time of the study, including department and institution. If authors are from more than one department or institution, each author’s initials should be placed in parentheses after the applicable address.
Running title, not to exceed 50 characters and spaces
Name and complete contact information for the corresponding author, including street address, telephone, fax, and e-mail address
Footnotes regarding change of address or affiliation, co-first authorship, or new sequence accession numbers
Statement (titled “Funding”) detailing any funding that supported the research
Statement (titled “Conflict of Interest”) detailing any conflicts of interest for all authors
Statement (titled “Authorship”) detailing the contributions of each author (see Authorship)
List of any unpublished papers cited (see Unpublished Material under References)
If applicable, a statement that the paper being submitted is one of a series
Mention of total manuscript word count, including words in abstract, text, references, and figure legends
Any deletions or additions to the author list after acceptance of the paper must be submitted in writing or by email, signed by all authors (including those added or deleted), to the Neuro-Oncology editorial office. Publication of manuscripts will be withheld until all such written approvals are received. Neuro-Oncology accepts no responsibility for such changes.
Similarly, all conflicts of interest (or relationships that would be suspected of constituting conflicts) should be declared and explained at the time of submission and reflect not only current conflicts but those in place at the time the research was conducted. Any changes made to the list of conflicts after the paper is accepted must be submitted in writing, signed by the appropriate authors (that is, the corresponding author and the author for whom the conflict exists), to the Neuro-Oncology editorial office. Publication of manuscripts will be withheld until all such written approvals are received. Neuro-Oncology accepts no responsibility for such changes.
Authorship
All authors listed on the manuscript should have contributed significantly to the experimental design, its implementation, or analysis and interpretation of the data. All authors should have been involved in the writing of the manuscript at draft and any revision stages, and have read and approved the final version.
A statement detailing the contributions of each author is to be included on the title page in the following format.
Contribution or task: author names or initials
Note: The number of regular authors is limited to 30. Any other individuals who contributed to the experiments or the writing of the manuscript should be listed in the Acknowledgment section. Group authorship: members of consortia or author groups may be listed, with affiliations, at the end of the text.
Authorship Requirements. For guidelines on authorship, please refer to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, formulated by the International Committee of Medical Journal Editors. The cover letter should state that all authors have seen and approved the manuscript.
Abstract
The abstract should not exceed 250 words. It should be written in full sentences. All abstracts, except those accompanying review articles, should be written in structured format:
Background : State the clinical (or other) importance of the work. End with a hypothesis or purpose statement (e.g., “The aim of this study was to determine whether…”).
Methods : Give the materials (or patients) and methods used to answer the research question.
Results : State the study’s findings. Make sure the results correspond to the methods.
Conclusions : In a sentence or two, explain how the findings address the purpose of the study. The conclusions should be supported by the results given.
Because abstracts often appear apart from the text of a paper (e.g., in PubMed or Medline), they should not cite references. Keep nonstandard abbreviations and acronyms to a minimum (no more than five in the abstract), defining them in parentheses at first mention. It is essential that the Abstract clearly states the biological importance of the work described in the paper.
Keywords
Below the abstract, list up to five keywords that may be used for indexing.
Key points
Below the key words, list two to three key points that summarize the most important findings of your manuscript. Each of these should be no longer than 85 characters plus spaces. These points may be used to highlight your article on social media.
Importance of the Study
All submissions to Neuro-Oncology should include a 150-word (or less) summary entitled "Importance of the Study". This should be placed just after (below) the abstract and keywords and include information regarding the value of the study compared with prior literature as well as future implications. For laboratory studies, a statement addressing the translational significance should be included. There should be no references. The Editors will use this information as part of the evaluation of the paper, and both the editors and peer reviewers will check the accuracy of the information and may ask for revision. This statement will also be published with the manuscript.
Text
Introduction . This section should state the problem or question being addressed and summarize relevant background information to provide context for the research question.
Materials and Methods. The explanation of the experimental methods should be brief but adequate for repetition by qualified investigators. Procedures that have been published previously may be described in brief and be cited with appropriate references. Only new and significant modifications of previously published procedures need complete exposition. The sources and manufacturers of special chemicals or preparations used should be named. Some of the methods details (buffer composition, PCR primers, incubation conditions, etc.) may be placed in a Methods supplement but each method must be mentioned in the main manuscript with enough information so that a reader does not have to consult the supplement to understand the procedures. Reference to the supplement should be made in the main manuscript text where appropriate. NOTE: Your ethics statement(s) must remain in the main manuscript.
For experimental investigations of human or animal subjects, state in the Methods section of the manuscript that an appropriate institutional review board approved the project. Investigators who do not have formal ethics review committees should follow the principles outlined in the "World Medical Association Declaration of Helsinki: Research involving human subjects". For investigations of human subjects, state in the Methods section the manner in which informed consent was obtained from the subjects. Statistical methods should also be clearly and completely described in the Methods section.
Special Requirements for pre-clinical studies:
If cell lines> are used, please note that experiments must be repeated in more than one cell line and/or neurosphere line.
Use of standard cell lines is discouraged. If these are used, the results should be validated with neurosphere cultures and patient derived xenografts.
In addition, please include a statement that addresses:
Where and when the cell lines were obtained,
Whether the cell lines have previously been tested and authenticated (e.g., by a cell bank),
The method by which the cell lines were tested and when the cell lines were tested.
For studies of microRNAs or experiments using CRISPR/Cas9:
At least two distinct sequences must be utilized, with a scrambled control sequence.
For CRISPR two or more edited clones are necessary.
For studies of biomarkers, please follow the REMARK guidelines. (see also PMID: 22675273)
Requirements for image integrity of western blots:
Cropped gels must retain important bands, and cropped blots should retain at least 6 bandwidths above and below band of interest.
Composite images must be explicit, e.g. lines should be present between lanes.
Some image manipulations may be acceptable, but they need to be described in detail.
High-contrast gels and blots should be avoided; overexposure may mask additional bands. If used, high-contrast blots should comprise a black line to indicate the borders of the blot.
All image acquisition tools and image processing software must be described in Material and Methods.
For genetic studies and sequence data:
Microarray data must be provided for peer review in a format that conforms to the Minimum Information About a Microarray Gene Experiment (MIAME) guidelines, available here. Data should be deposited in either of 2 public repositories — GEO or Array Express — and accession numbers should be given in the article.
New nucleotide or amino acid sequences must be deposited in GenBank, or outside of the USA in EMBL or the DNA Databank of Japan; accession numbers must appear in the manuscript.
Raw sequencing data must be deposited in either GEO or EGA. Guidelines for data protection must be respected.
Results. This section should include a concise summary of the data presented in the tables and illustrations. Excessive elaboration of those data should be avoided. The Results and Discussion sections may be combined if doing so saves space or improves the logical sequence of the material.
Discussion. The data should be interpreted concisely, without repeating material already presented in the Results section. Speculation is permissible, but it must be well founded and clearly identified as speculation.
Funding. Details of all funding sources for the work in question should be given in a separate section entitled "Funding". This should appear before the "Acknowledgments" section. The following rules should be followed: the full official funding agency name should be given (that is, "National Institutes of Health", not "NIH"); grant numbers should be given in brackets; multiple grant numbers should be separated by a comma; agencies should be separated by a semi-colon; no extra wording such as "Funding for this work was provided by ..." should be used; where individuals need to be specified for certain sources of funding, explanatory text should be added after the relevant agency or grant number "to [author initials]" (e.g., "National Institutes of Health (CB5453961 to C.S., DB645473 to M.H.); Funding Agency (hfygr667789).")
Acknowledgments (optional). An Acknowledgments section (not footnotes) should be included, if appropriate, to recognize the following:
Special assistance or contributions by non-authors (e.g., supply of materials or editorial support)
Previous presentation of the material at a meeting, workshop, or other event
Personal acknowledgments should precede those of institutions or agencies. Please note that acknowledgment of funding bodies and declarations regarding conflict of interest should be given in separate Funding and Conflict of Interest sections on the title page (see above).
References . See "References" for specific instructions.
Figure Captions . Figures should be numbered sequentially with Arabic numerals. Figures may have subparts (A, B, C, etc.); each subpart should be described in the caption. See recent issues of the journal for examples of acceptable styles.
Captions are required for all figures and should be typed, double-spaced, after the list of references. Captions should briefly describe the data shown and should not repeat details given in the text. Include the type of staining, magnification, and similar information required for accurate interpretation where applicable. Each caption should adequately identify all symbols (where not defined on the figure itself) and abbreviations used in the figure. Captions and symbols should make the figure interpretable without reference to the text. Figure numbers or captions should not be included on the face of an illustration.
Tables . Number tables with Arabic numerals. Tabular material should not simply duplicate data presented in the text or figures. Large groups of individual values should be avoided; instead, these should be averaged and an appropriate designation of the dispersion, such as standard deviation or standard error, included.
Tables should be typed in the manuscript file format, but minimizing redundant space; tables must include a short, descriptive title. Note that each column, including the first column, must carry an appropriate heading, and if numerical measurements are given, these units should be added to the column heading. Abbreviations used in the table should be defined in the table legend. Identify footnotes with superscript lowercase italic letters ( a, b, c , etc.).
Tables are uploaded as a separate file (or files) and are NOT part of the main manuscript file. All tables should be on separate pages. Tables should not have subparts, e.g. Table 1a, 1b, etc.
The format of tables should be in keeping with that normally used by the journal; in particular, vertical lines, colored text, and shading should not be used. Please be certain that the data given in tables are correct.
Special requirements for other articles
Clinical Trial Reports are formatted like clinical investigations. However, before submitting a clinical trial report, authors should consult the GNOSIS guidelines (published in the October 2005 issue of Neuro-Oncology [Vol. 7, Issue 4] [PDF]) and, to ensure completeness, crosscheck their manuscript against these guidelines. For negative studies, highest priority will be given to manuscripts that are written concisely.
Randomized controlled trials should conform to the Consolidated Standards of Reporting Trials (CONSORT) guidelines .
Review Articles should provide timely updates of advances in an area of neuro-oncology. Authors of unsolicited reviews should contact the Editor-in-Chief Kenneth Aldape, M.D. (Aldape.neuro.onc@gmail.com ) first to determine if the review is appropriate for Neuro-Oncology.
Because of the nature of review articles, which may cover a broad scope of topics related to the subject at hand, authors should use short headings to identify major manuscript sections (major and minor headings must be clearly identified by different-sized text). Though potentially broad in scope, reviews should be as concise as possible and should focus on seminal findings and important developments contributing to understanding of (or controversy about) the subject at hand.
Reviews should include maximally:
200-word abstract
7000 words of text and references combined
7 tables and/or figures
100 references
Meta-data Analyses/Reviews are based on detailed systematic analyses of clinical trials and studies that clearly delineate novel findings or solidify previously less well-substantiated results. Manuscripts should be written according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines; the use of the PRISMA checklist is encouraged. Meta-data Analyses/Reviews should include maximally:
250-word structured abstract (including Background, Methods, Results, and Conclusions)
150-word (max) Importance of the Study
7500 word-limit for all words in entire manuscript file*, including title page(s), abstract, importance, manuscript text, acknowledgements, references, and figure legends (but not tables)
7 tables and/or figures
100 references
*Please do not include supplementary legends in the main manuscript file.
Advances-in-Brief should provide brief updates of advances in a focused area of neuro-oncology. These are shorter than Reviews and provide either a brief review of important advances in the understanding of an aspect of biology pertinent to neuro-oncology, enhancing the understanding of articles published in Neuro-Oncology , or a thoughtful discussion of new paradigms important to the field. Advances-In-Brief will normally be solicited by the Editor-In-Chief; however, authors who wish to submit this type of article should contact the Editor-In-Chief, Kenneth Aldape, M.D. (Aldape.neuro.onc@gmail.com), first to determine if the article is appropriate for Neuro-Oncology .
Advances-in-Brief should include maximally:
200-word abstract
3500 words of text and references combined
5 tables and/or figures
50 references
Letters to the Editor addressing a recent publication in Neuro-Oncology or containing brief results or technical notes should give full contact information on the title page. They should include maximally:
600 words of text
1 simple table or figure (1 or 2 panels)
6 references
NO supplementary data
Editorials should include full contact/affiliation information on the title page and the statement that the text is the sole product of the author(s) and that no third party had input or gave support to its writing. Editorials should include maximally:
1000 words of text
1 simple table or figure
10 references (1 of these should be the subject article, if applicable)
Invited Meeting Reports should typically have a total length—including the title page, text, references, and tables or figures—of five printed pages (or about 15 typed pages).
……
